Last reviewed · How we verify

NCT05597371

An Analysis in the Use of Telecommunication Platform

Completed Last updated 24 February 2026
What this trial tests

trial testing the use of the platform in the Use of the Platform in 1,000,000 participants. Completed in 31 December 2025.

Timeline
1 January 2018
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorNational Taiwan University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,000,000
Start date1 January 2018
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

Eligibility, any sex, with the Use of the Platform. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The COVID-19 pandemic becomes a global challenge. Beneficial to being an island country and having appropriate policies, there were only few imported cases in Taiwan. However, many locally acquired cases came out in the mid of this May. The hospital policy about containing infection changed accordingly. A real-time communication platform for the health care workers was designed and embedded in the hospital information system of the emergency department in 2018. The functions included sending messages to certain staff, pop-up reminders, and tracking messages. This study aims to evaluate the use of the communication platform during the COVID pandemic.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05597371.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing